Gout incidence in metformin versus sodium–glucose co-transporter-2 inhibitor users: a retrospective cohort study
Gout risk may be comparable between metformin and SGLT-2is in individuals with diabetes, with metformin showing a lesser reduction in serum uric acid levels than SGLT-2is.
Authors
- Taku Saito (ORCID: https://orcid.org/0000-0003-4911-3930)
- Akira Okada (ORCID: https://orcid.org/0000-0001-6480-3388)
- Hisatoshi Ishikura (ORCID: https://orcid.org/0000-0001-6317-6087)
- Takeyuki Tanaka (ORCID: https://orcid.org/0000-0002-2040-6345)
- Sakae Tanaka (ORCID: https://orcid.org/0000-0001-9210-9414)
- Yusuke Sasabuchi (ORCID: https://orcid.org/0000-0001-7828-0549)
- Masaki Hatano (ORCID: https://orcid.org/0000-0002-7096-5604)
- Hideo Yasunaga (ORCID: https://orcid.org/0000-0002-6017-469X)
Institutions
- Tokyo University of Pharmacy and Life Sciences (JP)
- University of Tokyo Hospital (JP)
- University of Tokyo Health Sciences (JP)
- Department of Health (IE)
- Diagnostics for the Real World (United States) (US)
- The University of Tokyo (JP)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-03-24
- DOI
- https://doi.org/10.1093/rheumatology/keaf136
- Citations
- 2
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 2.86